Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more
Infant Bacterial Therapeutics AB (publ) - Asset Resilience Ratio
Infant Bacterial Therapeutics AB (publ) (IBT-B) has an Asset Resilience Ratio of 92.23% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Infant Bacterial Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Infant Bacterial Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr191.76 Million | 92.23% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr191.76 Million | 92.23% |
Asset Resilience Insights
- Very High Liquidity: Infant Bacterial Therapeutics AB (publ) maintains exceptional liquid asset reserves at 92.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Infant Bacterial Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio
Compare Infant Bacterial Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Infant Bacterial Therapeutics AB (publ) (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Infant Bacterial Therapeutics AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 93.25% | Skr223.39 Million | Skr239.57 Million | -0.41pp |
| 2023-12-31 | 93.66% | Skr329.06 Million | Skr351.33 Million | -2.40pp |
| 2022-12-31 | 96.06% | Skr335.84 Million | Skr349.62 Million | +1.38pp |
| 2021-12-31 | 94.68% | Skr386.75 Million | Skr408.48 Million | +0.65pp |
| 2020-12-31 | 94.03% | Skr423.44 Million | Skr450.32 Million | -1.51pp |
| 2019-12-31 | 95.55% | Skr495.19 Million | Skr518.27 Million | -0.69pp |
| 2018-12-31 | 96.24% | Skr542.17 Million | Skr563.37 Million | +5.81pp |
| 2017-12-31 | 90.43% | Skr158.27 Million | Skr175.02 Million | +5.25pp |
| 2016-12-31 | 85.18% | Skr93.79 Million | Skr110.11 Million | -- |